Product Description: Linifanib (ABT-869) (GMP) is Linifanib (HY-50751) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Linifanib is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (GMP) promotes the generation and reprogramming of iPSCs from somatic cells[1].
Applications: Cancer-Kinase/protease
Formula: C21H18FN5O
References: [1]Guan J, et al. Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature. 2022 May;605(7909):325-331.
CAS Number: 796967-16-3
Molecular Weight: 375.40
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: PDGFR;VEGFR